Description
Imricor Medical Systems
ASX: IMR · Early Commercial Stage · Medical Devices
The MRI Cath Lab
Investment Framework
Entry: A$1.95/sh · A$623m market cap · ~US$436m · March 2026
Horizon: 5 years to FY2031 · Single US$35m raise H1 2027 · 340m diluted shares at exit
Unit economics anchor: US$3m recurring revenue per top-100 US hospital at ~500 procedures/yr
Bear: ~(10)% IRR · 0.60x MOIC · 50 US labs, 20 EU labs, thin margins
Base: ~25% IRR · 3.05x MOIC · 75 US labs, 28 EU labs, $272m revenue
Bull: ~58% IRR · 9.87x MOIC · 125 US labs, 46 EU labs, $453m revenue
March 2026
This document is for informational purposes only and does not constitute investment advice. All financial estimates are the author's independent analysis. Figures in US$ unless stated.
TLDR
Imricor is building the first commercially viable MRI-guided cardiac ablation platform, a structural upgrade to a $12–14bn market still performed under X-ray. With a 15-year IP moat, no credible competitor, and a recurring consumable model, the business has the potential to compound into a high-margin installed-base story as adoption scales. At today’s valuation, the base case supports ~25% IRR with meaningful upside from both execution and strategic acquisition.
I. Company Overview
Imricor Medical Systems is a US-based medical device company founded in 2006 and listed on the Australian Securities Exchange (ASX: IMR). It is the only company in the world to have developed and commercially approved a suite of real-time MRI-compatible products for use in interventional cardiac procedures. The company's initial focus is the US$12-14 billion cardiac ablation market — the field of electrophysiology (EP) that treats life-threatening heart arrhythmias, which is currently conducted entirely under X-ray fluoroscopy. Imricor manufactures, sells, and licenses everything required to convert a hospital's existing MRI scanner into an interventional cardiac MRI (iCMR) laboratory capable of performing real-time MRI-guided ablation procedures. It captures 100% of the consumable revenue for every procedure performed in every lab it installs.
1.1 The Company's Origin and Technology Foundation
Steve Wedan, an electrical engineer who spent his career at GE Healthcare designing MRI and ultrasound systems, founded Imricor in 2006 after identifying the fundamental mismatch between what cardiac ablation requires and what fluoroscopy can provide. The original proof-of-concept for MRI-compatible cardiac catheters was developed at Johns Hopkins University, with the first paper published in 2008. Imricor licensed that foundational research and has spent the intervening fifteen years translating it into a commercially viable, fully validated product system. The company is headquartered and manufactures primarily in Minnesota. It listed on the ASX in August 2019, raising A$13 million at A$0.83 per share, and has since completed a series of equity raises totaling over A$200 million, most recently a A$70 million institutional placement in March 2025. As of December 2025 the company held US$40.8 million in cash with approximately 320.9 million shares on issue.
1.2 The Product Suite
Imricor's commercial proposition is an iCMR lab, a complete, purpose-built environment for performing real-time MRI-guided cardiac ablation. The lab consists of Imricor's own capital equipment, consumables, and software, combined with third-party MRI-safe peripherals and the hospital's existing MRI scanner. Every item Imricor sells or licences fits into one of three revenue categories.
Capital Equipment (one-time, ~50% gross margin)
The two pieces of capital equipment Imricor sells per lab installation are the RF5000 Ablation Generator and the MR Advantage EP Recorder/Stimulator. Together these are priced at approximately US$500,000-700,000 and constitute the hardware backbone of the iCMR lab. The ablation generator supplies and controls the radiofrequency energy delivered to the heart tissue. The EP recorder/stimulator captures intracardiac electrograms in real time, the electrical signals that tell the physician where the abnormal circuitry is, and can deliver pacing stimuli to provoke or assess arrhythmias during the procedure. Both are fully MRI-compatible, operating safely within the scanner's magnetic and radiofrequency environment without producing heat, artifacts, or interference.
NorthStar 3D Mapping System (annual licence, ~85% gross margin)
NorthStar is Imricor's proprietary 3D cardiac mapping and guidance platform, and arguably the most strategically important product in the portfolio. It is the central hub of every iCMR lab, the software layer that connects the MRI scanner, the catheters, and the physician. NorthStar receives real-time MRI images from the scanner, tracks the position of Imricor's catheters within the heart at approximately 20 updates per second using active tracking coils embedded in the catheter tips, builds a three-dimensional shell of the cardiac chamber from actual MRI anatomy, and overlays ablation target points and delivered energy markers onto the live image. The physician sees the heart, the catheter, and the ablation map simultaneously, in real time, without radiation.
Critically, NorthStar is vendor-neutral. It integrates with MRI scanners manufactured by GE, Siemens, and Philips — the three companies that together control essentially 100% of the global MRI installed base. A hospital does not need to replace its existing MRI scanner to install an iCMR lab; it only needs NorthStar and Imricor's consumables and capital equipment. NorthStar received CE Mark in Europe and FDA 510(k) clearance in the United States in January 2026. The US clearance was a significant milestone — it means Imricor can now have formal commercial conversations with US hospitals about full iCMR lab installation while the ablation catheter PMA progresses.
NorthStar is licensed at approximately US$100,000 per lab per year, creating an annuity-like recurring revenue stream that scales directly with the global installed base. As the installed base grows, this layer of predictable, high-margin license revenue compounds regardless of procedure volumes in any given month.
Consumables (~70% gross margin)
Consumables are the primary revenue engine at scale. Every procedure performed in an iCMR lab requires a set of single-use Imricor-manufactured devices, which the company sells directly at the following approximate US price points:
Product
Function
US ASP
Indication
Vision-MR Ablation Catheter 2.0
Delivers radiofrequency energy to target cardiac tissue; contains MRI tracking coils and passive LC filter circuitry
~$4,000 (AFL) ~$6,500 (VT/AF)
AFL (CE Mark); VT/AF (in development)
Vision-MR Diagnostic Catheter
Records intracardiac electrograms to map arrhythmia; guides catheter placement pre-ablation
Included in procedure ASP
All indications
Transseptal Puncture Kit
Enables safe crossing from the right to the left atrium — required for AF and some VT procedures
Included in procedure ASP
AF / left-sided VT
Dispersive Electrode
Large body patch that completes the radiofrequency electrical circuit; MRI-compatible formulation
Included in procedure ASP
All indications
NavTrac-MR Sterile Cables
MRI-shielded cables connecting catheters to the generator and EP recorder
Included in procedure ASP
All indications
The ablation catheter is the primary consumable value driver. It is Imricor's most complex manufactured product. Each catheter contains the proprietary passive LC filter architecture that makes MRI compatibility possible, an irrigated radiofrequency tip, MRI receive coils for active catheter tracking, and a fiber-optic temperature sensor. CE Mark approval for the second-generation Vision-MR Ablation Catheter 2.0 was received in 2025. US FDA PMA approval, the pathway for the ablation catheter and generator, is the critical remaining regulatory event, with the VISABL-AFL pivotal trial nearing completion and full PMA submission targeted for mid-2026.
1.3 Third-Party Lab Components
Several components of the iCMR lab are supplied by third-party partners rather than Imricor directly. These include MRI-compatible wireless headsets for team communication within the scanner room (Optoacoustics), a 12-lead ECG monitor (MiRTLE Medical), an MRI-safe defibrillator (MIPM), and in-room displays (Nordic NeuroLab). The MRI scanner itself, the most capital-intensive element, is purchased directly from GE, Siemens, or Philips; Imricor does not participate in scanner revenue. This ecosystem of validated third-party relationships took years to assemble and is itself a component of the competitive moat: any new entrant would need to replicate not just Imricor's catheters but the entire validated lab environment.
1.4 Regulatory Status and Clinical Program
Imricor has achieved CE Mark under the EU Medical Device Regulation, the most rigorous European framework, for the full AFL ablation product suite: ablation catheter, diagnostic catheter, NorthStar, generator, cables, and electrodes. This permits commercial sales across Europe for atrial flutter ablation today. In the United States, NorthStar is FDA-cleared via 510(k). The ablation catheter and generator are in Pre-Market Approval (PMA), with the VISABL-AFL clinical trial, the pivotal US study enrolling at Johns Hopkins, University of Virginia Health, Virginia Commonwealth University Health, and Oklahoma Heart Institute, nearing completion.
Two further trials are active. The VISABL-VT trial, which enrolled its first patient in April 2025 at Amsterdam University Medical Centre, is the pivotal European study for VT CE Mark and is progressing at three EU sites. A separate program of first-in-human PFA (pulse field ablation) catheter development under real-time MRI guidance has also been initiated, following the world's first in-vivo MRI-guided ventricular PFA ablation completed in 2025.
Imricor at a Glance
Founded: 2006 · Listed ASX: August 2019 · HQ: Minnesota, USA
Shares on issue: 320.9 million · Cash (Dec 2025): US$40.8m
Key products: NorthStar 3D Mapping System · Vision-MR Ablation Catheter 2.0 · RF5000 Generator · MR Advantage EP Recorder/Stimulator · Full consumable suite
Regulatory: CE Mark (full AFL suite) · NorthStar FDA 510(k) cleared Jan 2026 · Ablation catheter PMA in progress (US)
Clinical: VISABL-AFL (US PMA trial, 4 US sites) · VISABL-VT (EU CE Mark trial, 3 EU sites) · PFA catheter development underway
Market: US$12-14bn cardiac ablation market growing at ~15% CAGR · Three arrhythmia indications: AFL, VT, AF · Currently conducted 100% under X-ray
Revenue model: Capital sale (~$500-700k/lab) · NorthStar licence (~$100k/lab/yr) · Consumables (~$4,000-6,500/procedure) · 100% of consumable revenue captured per lab
II. Why MRI Is the Superior Modality
Cardiac ablation has been performed under X-ray fluoroscopy for four decades. The procedure requires navigating a catheter through a beating heart, identifying the precise fragment of tissue responsible for an electrical abnormality, applying energy to destroy it permanently, and confirming the result before closing. Fluoroscopy is a structurally poor fit for this job. It was engineered to image bone and calcified structures, not soft cardiac tissue. Everything the operator cannot see must be inferred from indirect markers.
1.1 The Four Failures of X-Ray
The first failure is anatomical visualization. Under fluoroscopy, operators build a three-dimensional map of the cardiac chamber by touching the catheter tip to hundreds of points on the wall, assembling a surface approximation that represents the anatomy but cannot show the tissue beneath it. In ventricular tachycardia, where the target is a narrow channel of surviving myocardium embedded within scar, this is an acute limitation. The channel sustaining the arrhythmia may be millimeters wide and invisible without the soft-tissue contrast that only MRI provides.
The second failure is lesion verification. When radiofrequency energy is delivered under X-ray, there is no way to confirm in real time whether the lesion is transmural, whether cell death is complete, or whether an unintended gap has been left. Electrical silence at the catheter tip is used as a proxy, but gaps in pulmonary vein isolation and incomplete cavotricuspid isthmus block are principal causes of arrhythmia recurrence. Published series for atrial flutter report 10-20% long-term recurrence after a single ablation; for atrial fibrillation, five-year recurrence exceeds 30%.
The third failure is procedure time. A complex VT ablation under fluoroscopy takes five to nine hours on average, driven by the time required to build the electroanatomic map before a single ablation can be delivered. Each additional hour occupies expensive infrastructure and burdens a hemodynamically fragile patient.
The fourth failure is radiation: each ablation exposes the physician to ionizing radiation equivalent to a chest CT. Physicians performing 300-400 cases per year accumulate a substantial cumulative dose, with documented occupational consequences including musculoskeletal injury from lead aprons, cataracts, and elevated cancer risk.
1.2 What Real-Time MRI Delivers
Real-time MRI provides live, high-resolution, multiplanar soft-tissue contrast of a beating heart. The operator sees the myocardium directly, distinguishes viable tissue from scar, and tracks the catheter relative to the anatomy as it actually exists, not as a reconstructed approximation. In VT, the arrhythmogenic scar channel is visible before the first catheter contact. In AFL, the cavotricuspid isthmus is confirmed against the actual tissue rather than an inferred map.
Ablation lesion assessment in real time is MRI's most distinctive clinical capability. Gadolinium-enhanced imaging identifies edema and necrosis within minutes of energy delivery, giving the operator direct confirmation that the lesion is complete before moving to the next target. Imricor's CE mark enabling trial in AFL demonstrated 100% arrhythmia-free survival at two-year follow-up versus the 70-80% typically reported in fluoroscopy-guided published series.
Procedure time compression, consumable savings, and radiation elimination follow from the visualization advantage. Removing the intracardiac echocardiography catheter, eliminating point-by-point mapping in VT, and reducing repositioning uncertainty all shorten procedures. Imricor's first-in-human ischemic VT ablation was completed in a fraction of the time required under fluoroscopy. These advantages compound: shorter procedures mean higher throughput; better first-procedure success means fewer repeat ablations; lower consumable cost means higher per-case margin for the hospital.
The Clinical Case
Superior visualization + real-time lesion confirmation + shorter procedures + zero radiation compounds into one outcome: higher first-procedure durability and fewer repeat ablations. These are not marginal improvements. They represent a categorical change in what the procedure can achieve and why the adoption curve, once established, is likely to be self-reinforcing as outcome data accumulates at scale.
III. Why This Is Hard to Build — and Why the Moat Is Real
If the clinical advantages are self-evident, why did it take fifteen years and one company to commercialize the solution? The answer is an intersection of engineering, ecosystem, and regulatory challenges that are individually demanding and collectively near-prohibitive for any new entrant.
2.1 The Electromagnetic Incompatibility Problem
An MRI scanner generates a magnetic field of 1.5 to 3 Tesla and pulses radiofrequency energy at the resonant frequency of hydrogen protons: 64 MHz at 1.5T, 128 MHz at 3T. Any conductive material inside the bore acts as an antenna: it absorbs the RF energy, develops dangerous localized heating at the electrode tip, and produces imaging artifacts that obscure the anatomy. A conventional ablation catheter is not merely suboptimal inside an MRI; it is actively dangerous.
Imricor's foundational innovation is a passive dual-filter circuit architecture embedded in the catheter. Distributed non-resonant inductors along the electrode wires limit RF-induced current build-up at the scanner's operating frequency. Resonant LC filters provide high impedance that reflects MRI-induced energy before it reaches the electrode tip. Ablation current, which operates at much lower frequencies, passes through the same circuit with negligible attenuation. The result: a catheter that simultaneously delivers therapeutic energy, records intracardiac electrograms, and is tracked in real time under MRI without heating, without artifacts, without any active component.
The impedance is fixed at manufacture by the coil geometry. No calibration, no power source, no software. This makes the catheter both reliable and manufacturable at scale. It is protected by 19 issued US patents and 71 granted foreign patents, covering catheter circuit architectures, tracking coil designs, cable technologies, and deflection mechanisms, with filing dates from 2010 to 2042.
2.2 The Full Ecosystem Problem
A cardiac ablation procedure requires a complete working environment: 3D cardiac mapping, electrogram recording and pacing, energy delivery control, patient monitoring, hemodynamic support, and emergency defibrillation all within a room dominated by a 1.5 Tesla magnetic field. Every instrument that enters the MRI suite must be purpose-built for this environment. Off-the-shelf hospital equipment cannot be used.
Imricor has assembled this complete ecosystem over fifteen years: the Vision-MR Ablation and Diagnostic Catheters; the NorthStar 3D Mapping System (vendor-neutral, works with GE, Siemens, and Philips); the MR Advantage EP Recorder/Stimulator; the RF5000 Ablation Generator; sterile cables, transseptal puncture kits, and dispersive electrodes. Third-party partnerships with Optoacoustics, MiRTLE Medical, and MIPM complete the lab. The vendor-neutral NorthStar architecture means hospitals with any of the three major MRI platforms can deploy iCMR without replacing their existing scanner.
2.3 The Regulatory Moat
The regulatory pathway for an MRI-compatible cardiac ablation platform is the pathway for a complete system; each component requiring independent authorization across multiple jurisdictions. In Europe, CE Mark under the Medical Device Regulation has been granted for the full AFL ablation product suite. In the United States, NorthStar has been cleared via 510(k). The ablation catheter and generator are progressing through Pre-Market Approval, with modules 1 and 2 submitted and module 3 approaching completion.
Any new entrant must design a full catheter system, establish MRI electromagnetic compatibility at the circuit level, run multi-site prospective clinical trials, and navigate a PMA process, a five to seven year timeline requiring hundreds of millions of dollars. Biotronik ran one patient in Germany and stopped. Clearpoint Neuro never approached cardiac ablation. The regulatory moat is not a temporary first-mover advantage. It is a structural barrier that deepens as Imricor accumulates clinical and commercial data.
Five Layers of Competitive Protection
• Proprietary passive circuit IP covering the fundamental electromagnetic compatibility problem (19 US patents, 71 foreign, 2010–2042)
• Complete validated lab ecosystem assembled over 15 years - catheters, generator, mapping system, cables, third-party partnerships
• CE Mark granted; US PMA advancing - not replicable quickly by any new entrant
• Deep KOL relationships at leading EP centers - four active VISABL-AFL US trial sites including Johns Hopkins and Oklahoma Heart Institute
• Vendor-neutral NorthStar compatible with GE, Siemens, and Philips - converts existing hospital MRI into an iCMR lab without scanner replacement
IV. Value Creation Across All Stakeholders
A technology platform achieves durable commercial success when adoption is independently rational for every party in the ecosystem. The iCMR platform is notable in that this alignment is near-complete. Patients, physicians, hospitals, and payers each have separate and mutually reinforcing incentives to adopt. The commercial question is not whether iCMR becomes standard of care. It is how fast the ecosystem converts.
3.1 Patients
The core promise for the patient is durability, a single curative procedure rather than a sequence of ablations separated by months of symptomatic recurrence. The AFL trial two-year follow-up data, 100% freedom from arrhythmia versus 70-80% under fluoroscopy, is directionally compelling: when the operator can see the target tissue and confirm the lesion is complete, the procedure works better. VT patients represent the most acute clinical case, typically post-infarction, often hemodynamically fragile, and historically underserved because the procedure is too arduous to offer routinely. Real-time MRI visualization of scar architecture could change the risk-benefit calculation for VT ablation across a much broader population.
3.2 Physicians
More precise visualization means more confident lesion delivery and fewer cases in which the operator ends the session uncertain whether the ablation is complete. For VT, where the substrate is invisible under fluoroscopy, the advantage is categorical. The radiation argument compounds this: physicians performing 300-400 ablations per year accumulate documented occupational exposure. Several KOLs enrolled in Imricor's trial program have explicitly cited radiation elimination as a meaningful benefit independent of the clinical outcomes data. The generation of electrophysiologists entering practice today has markedly higher awareness of this risk than their predecessors.
3.3 Hospitals
The unit economics argument is direct and grounded. Imricor's system eliminates the intracardiac echocardiography catheter (approximately US$2,000 per case) used in left-sided procedures, and removes the dedicated electroanatomic mapping catheter in VT and AF (approximately US$2,000 per case). Against Medicare reimbursement of approximately US$24,500 per ablation, and commercially insured cases at US$51,000-56,000, a US$4,000 per-case reduction in consumable cost flows directly to hospital margin. The iCMR lab is less expensive to run per procedure than the conventional fluoroscopy workflow.
Throughput is the amplifier. A VT ablation reducible from seven hours to three to four hours under MRI guidance allows a high-volume center to run two cases in the time that previously accommodated one. An MRI scanner's dual-use capability, diagnostic cardiac imaging between ablation sessions, extends the utilization argument beyond the EP lab. And for the 15-20 major US academic centers already with MRI infrastructure in cardiology, adding Imricor's system costs US$500,000-700,000, a fraction of the US$3-4 million required to replace a fluoroscopy system at end-of-service-cycle.
3.4 Payers
Existing reimbursement codes cover iCMR ablation without modification. AFL, AF, and VT ablation are reimbursed under APC 5213 at approximately US$24,500 per Medicare case; commercial rates run US$51,000-56,000. Reimbursement increased 8% between FY24 and FY25. The payer's long-term interest, lower total pathway cost through fewer repeat procedures, is aligned with the technology's clinical promise. No new payer negotiation is required for Imricor to generate revenue.
Stakeholder
Primary Value Driver
Mechanism
Patient
Higher single-procedure durability; zero radiation
AFL: 100% 2yr recurrence-free vs ~75% fluoroscopy; VT: direct scar visualization
Physician
Better visualization; radiation eliminated; faster complex cases
Zero occupational exposure; direct substrate imaging in VT; procedure time compression
Hospital
Lower per-case cost; higher throughput; dual-use MRI
~US$4k/case consumable savings; 2x throughput potential for long VT; $500k vs $4m capex
Payer
Lower lifetime pathway cost per patient
Fewer repeat ablations; existing APC 5213 codes apply; Medicare rate +8% FY24-25
V. Approval Timeline and Revenue Architecture
The Imricor investment reduces to three sequential variables: when does US FDA approval arrive, how quickly do hospitals install iCMR labs, and how fast do procedure volumes ramp within those labs. The clinical and moat arguments are established. The investment uncertainty is concentrated in the timing and cadence of execution across these three variables.
4.1 Regulatory Status
In Europe, CE Mark under the full Medical Device Regulation has been granted for the complete AFL ablation product suite allowing commercial sales across the EU now. The 40-hospital European pipeline represents active near-term revenue. In the United States, NorthStar has been FDA-cleared via 510(k), allowing Imricor to begin formal commercial discussions with US hospitals ahead of catheter approval. The ablation catheter and RF5000 Generator are in the PMA process: modules 1 and 2 submitted, module 3 approaching submission, with VISABL-AFL trial completion expected 1H 2026 and full PMA submission thereafter. Standard FDA PMA review runs 10-12 months, implying approval in H2 2026 in the base case.
The four active US VISABL-AFL trial sites, Johns Hopkins, University of Virginia Health, Virginia Commonwealth University Health, and Oklahoma Heart Institute, are among the most prestigious EP programs in the country. These are pre-seeded commercial accounts: staff are trained, labs are configured, and physicians are publicly committed to the technology. Post-approval, converting a trial site to a commercial account is a contract negotiation, not a new sales process.
The VISABL-VT trial enrolled its first patient in April 2025 and is advancing at three European sites. Trial completion and VT CE Mark are targeted for 2027, opening Europe's highest-value consumable category at US$6,500 per procedure and providing the clinical package for a US VT program.
4.2 Revenue Model
Imricor's revenue has three components with distinct margin profiles. Capital sales, the ablation generator, EP recorder/stimulator, and NorthStar system, generate US$500,000-700,000 per lab installed at approximately 50% gross margin. Annual NorthStar license fees of approximately US$100,000 per lab carry approximately 85% gross margin and build a recurring, predictable revenue base that scales with the installed count. Consumable sales, catheters, kits, cables, and electrodes priced at US$4,000-6,500 per procedure, carry approximately 70% gross margin and are the primary revenue and cash flow engine at scale.
As the revenue mix shifts from capital-heavy early installs toward consumable and licence-dominated recurring revenue, blended gross margin converges toward 65-70%. Fixed cost leverage, R&D plateauing at approximately US$11-13 million annually, G&A growing modestly, drives EBITDA margin expansion from gross margin gains. EBITDA profitability is expected from FY29 onward in the base case. Free cash flow conversion from EBITDA at scale is estimated at approximately 80%, reflecting light capital expenditure requirements and modest working capital growth as procedures ramp.
VI. Unit Economics: Building Revenue from the Lab Up
The revenue scenarios in Section VI are not derived from top-down market penetration assumptions. They are built from the bottom up, starting with a single installed iCMR lab and scaling the number of labs installed across geographies and years. This section lays out the unit economics behind each lab, so the revenue assumptions can be stress-tested against what individual hospitals are expected to contribute.
5.1 The Economics of a Single US iCMR Lab
The anchor assumption, informed by Imricor's own investor materials and cross-checked against EP procedure volume data at large US academic centers, is approximately US$3 million in annual recurring revenue per top-100 US hospital, based on approximately 500 ablation procedures per year per iCMR lab. This figure combines consumable revenue and annual license fees.
Per-Lab Unit Economics: Top-100 US Hospital
Procedure volume: ~500 procedures per year per iCMR lab
Procedure mix: AFL (~30% of eligible cases), VT (~100% of referred cases), AF (~20% of recurrent cases)
Blended consumable ASP: ~US$5,500 (AFL at $4,000; VT and AF at $6,500)
Consumable revenue: 500 procedures × US$5,500 = US$2,750,000 per year
NorthStar license: US$100,000 per year
Service fees: US$150,000 per year
Total recurring revenue: US$3,000,000 per year per lab
One-time capital revenue: US$600,000 (generator + EP recorder/stimulator) — recognized at installation
Gross profit on recurring: Consumables at 70% = $1,925k · License at 85% = $85k · Service at 85% = $128k
Recurring gross margin: ~$2,138k / $3,000k = ~71% blended gross margin on recurring revenue
The 500-procedure-per-year assumption is conservative relative to the volumes at the largest US academic EP centers. Imricor's own data shows that the top 50 US hospitals by volume perform on average 434 AFL, 173 VT, and 1,010 AF procedures annually, a total addressable pool of approximately 1,617 ablation procedures per hospital, of which 500 represents a 30-35% penetration rate. As physician familiarity grows, lab utilization increases, and the VT and eventually AF indications open, the per-lab revenue figure has meaningful upside from this base.
5.2 EU and ROW Lab Economics
European and ROW hospitals generate lower per-procedure revenue for Imricor due to lower consumable ASPs, reflecting different reimbursement structures and purchasing dynamics. We model EU consumable revenue at approximately US$1,500-2,500 per procedure for AFL (versus US$4,000 in the US) and approximately US$3,500-4,000 for VT and AF (versus US$6,500 in the US). At ~300 procedures per EU lab per year, this produces approximately US$0.9-1.2 million in annual recurring revenue per EU iCMR lab, roughly half the US figure. Capital revenue per EU lab is approximately US$300,000.
5.3 Revenue Build by Installed Base
The table below shows the direct relationship between the number of installed labs and annual recurring revenue, providing a simple bridge between the lab count in each scenario and the revenue targets. Capital revenue, which is lumpy and depends on the pace of new installations in any given year, is shown separately, using a conservative assumption that 25% of the installed base represents new installs in each year (reflecting an accelerating install curve).
US Labs (Mature)
EU Labs (Mature)
US Recurring
EU Recurring
Total Recurring
Est. Capital p.a.
25
9
$75m
$10m
$85m
+$5m
50
19
$150m
$21m
$171m
+$11m
75
28
$225m
$31m
$256m
+$16m
100
37
$300m
$41m
$341m
+$21m
125
46
$375m
$51m
$426m
+$27m
150
56
$450m
$62m
$512m
+$32m
The US TAM extends well beyond 150 hospitals. Any hospital with an MRI scanner and an active EP program is a potential iCMR site, a population of over 1,200 institutions in the US alone.
5.4 Procedure Ramp Within Installed Labs
Labs do not operate at full utilization immediately upon installation. Staff training, physician scheduling, and patient referral network development mean that a newly installed iCMR lab typically reaches 60% of its steady-state procedure volume in the first year and full utilization by year two. This ramp effect means that the installed base at any point in time generates less revenue than a fully mature installed base of the same size, and it is one of the reasons the revenue trajectory in the early years of a scenario can appear slow relative to the eventual run-rate contribution of each lab installed.
The year-by-year revenue trajectory in each scenario in Section VI accounts for this ramp, applying a 50-60% utilization assumption in the year of installation and full utilization from the following year. New capital installations in each year generate proportionally lower consumable revenue than the existing base — which is why revenue growth accelerates as the installed base matures and procedures deepen within each lab.
VII. Return Analysis: A 5-Year IRR Framework
We frame the investment as a return question: given the current entry market capitalization, what does the company need to become by FY2031 to generate a target return? We present a range of valuation methodologies benchmarked against comparable MedTech M&A transactions and public comps.
6.1 Framework and Assumptions
Entry market capitalization: approximately A$622 million (US$436 million at A$/USD 0.70). Holding period: five years to FY2031. A single equity raise of approximately US$35 million in H1 2027 results in approximately 340 million diluted shares at the exit date, the only dilution modeled. EBITDA and FCF multiples of 16-25x and 20-30x respectively are consistent with comparable medical device companies at similar stages of recurring revenue scale.
6.2 Margin Assumptions
The margin build from near-zero gross profit today to the FY31 profiles below is driven by the mix shift from capital sales (50% gross margin) to consumables and licenses (70-85% gross margin) as the installed base grows, and by fixed cost leverage as R&D and G&A grow more slowly than revenue. FCF conversion from EBITDA is estimated at approximately 78-84% at scale, reflecting light capital expenditure and manageable working capital growth.
Margin Metric
FY26E (Base)
FY28E (Base)
FY31E Bear
FY31E Base
FY31E Bull
Blended Gross Margin
~22%
~58%
~55%
~66%
~70%
EBITDA Margin
Neg
~5%
~8%
~25%
~38%
FCF Margin
Neg
Neg
~6%
~20%
~32%
FCF / EBITDA Conversion
n/m
n/m
~75%
~80%
~84%
R&D (US$m)
~$10
~$11
~$12
~$13
~$16
G&A (US$m)
~$6
~$7
~$8
~$10
~$13
6.3 Revenue Trajectory
Revenue in each scenario is anchored to the lab counts at FY31: 50 US + 20 EU labs in the bear, 75 US + 28 EU in the base, and 125 US + 46 EU in the bull. The year-by-year build reflects EU commercial momentum in FY26-27, US commercial launch following FDA approval in FY27-28, and procedure ramp deepening within the global installed base through FY29-31. The VT CE Mark in 2027 is the most significant single revenue catalyst within the forecast period. It opens the US$6,500 per procedure consumable category across the growing installed base.
FY26E
FY27E
FY28E
FY29E
FY30E
FY31E
Bear Revenue (US$m)
$4
$8
$20
$60
$115
$182
Base Revenue (US$m)
$4
$12
$55
$120
$195
$272
Bull Revenue (US$m)
$6
$20
$90
$200
$330
$453
Bear Global Lab Count
4
6
15
35
55
70
Base Global Lab Count
6
12
30
60
88
103
Bull Global Lab Count
8
20
55
105
145
171
6.4 Scenario Outcomes and IRR
The IRR in each scenario is driven by the EV/EBITDA exit multiple applied to the EBITDA the company generates at its FY31 revenue level. FCF is shown for reference, and the implied EV/FCF multiple — derived from the same exit EV — serves as a reasonableness check. EV/Revenue is shown as a comp check as well.
Metric
Bear Case
Base Case
Bull Case
FY31E Revenue (US$m)
$182m
$272m
$453m
── Recurring (consumables + lic)
$171m
$250m
$426m
── Capital (installations)
$11m
$16m
$27m
FY31E US / EU Labs
50 / 20
75 / 28
125 / 46
FY31E Gross Margin
~55%
~66%
~70%
FY31E EBITDA (US$m)
$15m
$68m
$172m
FY31E EBITDA Margin
~8%
~25%
~38%
FY31E Free Cash Flow (US$m)
$11m
$53m
$145m
FY31E FCF Margin
~6%
~20%
~32%
── EV/EBITDA exit multiple
18x
20x
25x
Exit EV (US$m)
$270m
$1,330m
$4,304m
─── 5-Year IRR
(10)%
25%
58%
─── 5-Year MOIC
0.60x
3.05x
9.87x
Implied A$/share
A$1.10
A$5.59
A$18.08
Implied EV/FCF (cross-check)
24.0x
25.0x
29.7x
Implied EV/Revenue (cross-check)
1.4x
5.0x
9.5x
6.5 Gross Profit Sensitivity
A strategic acquirer would likely evaluate Imricor within the context of its own cost structure, where existing sales, R&D, and G&A capabilities may reduce the relevance of standalone EBITDA. In that setting, EV relative to gross profit can be a useful framing.
The grid below fixes the gross margin at 66%, the base case assumption, and shows the 5-year IRR at each lab count and EV/GP multiple. Each row represents a different installed base at maturity; the gross profit at each row is purely a function of the recurring revenue those labs generate. The base case row, 75 US labs plus 28 EU labs producing US$179 million of gross profit, requires approximately 8x EV/GP to generate a ~25% IRR from today's entry. Rows above it represent faster adoption curves; the multiple required to hit 25% IRR falls as the installed base grows.
Lab Count (GP at 66% GM) \ EV/GP
4x
5x
6x
7x
8x
9x
10x
25 US + 9 EU ($60m GP)
-11%
-7%
-4%
-1%
2%
4%
6%
50 US + 19 EU ($120m GP)
2%
7%
11%
14%
17%
20%
22%
75 US + 28 EU ($179m GP) ← base
10%
16%
20%
24%
27%
30%
33%
100 US + 37 EU ($239m GP)
17%
22%
27%
31%
34%
38%
41%
125 US + 46 EU ($298m GP)
22%
28%
33%
37%
41%
44%
47%
150 US + 56 EU ($359m GP)
27%
33%
38%
42%
46%
49%
52%
Gross margin fixed at 66%. GP = (US labs × $3.0m + EU labs × $1.1m + capital) × 66%. Green ≥25% Teal 15–24% Amber 0–14% Red Negative · Entry = US$436m · 5-year horizon
VIII. Acquisition Analysis
In our view, the most likely outcome for Imricor is an acquisition by one of the large MedTech or imaging companies for whom owning this platform is strategically compulsory. Every major player in cardiac electrophysiology or MRI has either tried and failed to build what Imricor has built, or operates a franchise that Imricor's technology directly threatens or enhances. The IP, the regulatory approvals, and the installed base are not replicable on any reasonable timeline, which is precisely the condition under which strategic acquirers pay the largest premiums.
This section is intentionally separate from the earnings-driven return analysis in Section VII. The acquisition scenario does not depend on Imricor reaching a specific EBITDA margin or FCF conversion rate. It depends on a strategic buyer deciding that the cost of acquiring the platform is lower than the cost of competing against it or rebuilding it internally, a calculation that favors acquisition across a wide range of revenue and margin outcomes.
7.1 Who Buys This and Why
There are six credible acquirers, each with a distinct and specific rationale.
Acquirer
Strategic Rationale
What They Get
GE HealthCare
NorthStar runs natively on GE MRI scanners. Acquiring Imricor converts GE's existing cardiology MRI installed base, thousands of scanners already in EP-capable hospitals, into a recurring procedural revenue stream. Every GE scanner becomes a potential iCMR lab without a scanner replacement cycle.
Installed base monetization; procedure revenue on existing hardware; lock-in for next MRI refresh cycle
Siemens Healthineers
Siemens has been the most aggressive of the three MRI majors in pursuing imaging-therapy convergence. Their ARTIS icono hybrid OR platform reflects exactly this strategic intent. iCMR is the cardiac ablation expression of that strategy, and Siemens has no internal program in this space.
Cardiac therapy convergence; completes EP strategy without years of development; vendor-neutral NorthStar flips to Siemens-preferred
Philips
Philips attempted MRI-guided cardiac therapy internally and discontinued the program. They carry the institutional knowledge of how hard this problem is and the cost of having failed. Acquiring Imricor eliminates the competitor they failed to build and re-enters the market with a proven system.
Eliminates existential competitive gap; re-entry into MRI-guided therapy; IP acquisition removes rebuild risk entirely
Medtronic
Medtronic acquired Affera in 2022 for ~US$925 million pre-revenue, specifically to enter the EP mapping and navigation market. Affera operates under fluoroscopy. Imricor adds the MRI imaging layer that Affera lacks, combining with Medtronic's existing ablation catheter portfolio to create the only fully integrated conventional + MRI EP platform.
MRI layer for Affera; complete multi-modality EP franchise; VT substrate mapping advantage across both fluoroscopy and MRI labs
Boston Scientific
BSc's Farapulse PFA platform exceeded US$1 billion in its first full year. Farapulse operates under X-ray. Imricor is developing an MRI-compatible PFA catheter — a product that, if it reaches market independently, becomes the direct competitive threat to Farapulse in high-complexity AF and VT. Acquiring Imricor before that product matures removes the threat and adds MRI capability to the BSc EP franchise.
Pre-empts MRI-PFA competitive threat; adds MRI guidance to Farapulse ecosystem; VT market entry via iCMR
J&J / Biosense Webster
Biosense Webster's CARTO system is the global standard for EP mapping under fluoroscopy. Imricor's NorthStar is, structurally, CARTO for the MRI era, the same mapping and guidance role, executed under a superior imaging modality. J&J has spent over US$30 billion on cardiac MedTech since 2022. Adding iCMR capability extends the Biosense Webster franchise into the next imaging generation.
NorthStar as CARTO successor platform; dominant mapping franchise extended to MRI; natural evolution of $30bn+ cardio build-out
7.2 Acquisition Timing and Valuation
The relevant precedent transactions establish the valuation framework. Medtronic paid approximately US$925 million for Affera in 2022, a pre-revenue EP mapping and ablation company with investigational technology, no commercial sales, and a single pivotal trial in progress. The strategic rationale was identical to the case for acquiring Imricor: filling a gap in the EP portfolio that could not be bridged through internal R&D on a competitive timeline. J&J paid approximately US$13.1 billion for Shockwave Medical in 2024 at roughly 18x trailing revenue, on 49% annual revenue growth, for a platform with genuine market leadership and defensible IP in a large underpenetrated cardiovascular market. These two transactions bracket the Imricor acquisition spectrum, from IP buy at minimal revenue to scale premium at established growth.
Imricor's most relevant comp at any acquisition point is not a company at steady-state earnings. It is a platform with a patented technology moat, a complete validated ecosystem that took 15 years to assemble, regulatory approvals that no competitor has replicated, and a recurring consumable model that accelerates as labs mature. Acquirers in this category routinely pay on forward revenue trajectory rather than current earnings, and the strategic premium reflects the cost of the alternative: attempting to rebuild the platform internally, which the three MRI OEMs, Medtronic, BSc, and J&J have all either tried and failed or explicitly chosen not to attempt.
7.3 Acquisition Scenario Outcomes
The table below shows indicative acquisition outcomes across three timing scenarios. Revenue multiples are applied to estimated revenue at each acquisition date, using a range of multiples anchored to comparable cardiac MedTech transactions. IRRs are computed from the current entry market cap of US$436 million. A pre-revenue or near-revenue acquisition (FY26-27) is treated as an IP and pipeline acquisition analogous to Affera, with an absolute EV range rather than a revenue multiple.
Scenario
Timing
Est. Revenue
EV Range (US$m)
Multiple Basis
IRR Range
A$/Share
Pre-approval / IP buy
FY26-27 (1-2 yrs)
US$10-30m
$800m – $1,500m
IP + regulatory pathway; Affera comp ($925m pre-rev)
50–100%+
A$3.36 – A$6.30
Early commercial
FY28 (~3 yrs)
US$50-80m
$780m – $1,200m
12–18x EV/Rev; 50-80 labs installed
21–40%
A$3.28 – A$5.04
At scale
FY30-31 (~5 yrs)
US$220-330m
$2,200m – $5,000m
10–15x EV/Rev; 100+ US labs, VT + AF
38–62%
A$9.24 – A$21.01
A few observations on this table. The pre-approval scenario IRR is very high but also the least probable: large MedTech acquirers move slowly, and a transaction before FDA PMA approval carries regulatory risk that most buyers price conservatively. The most likely acquisition window is the early commercial phase, FY28, after the US commercial model has been validated by 30-50 lab installations but before the revenue trajectory is fully visible. This is when acquirers have sufficient data to underwrite the platform while the target's negotiating position has not yet fully reflected the bull case revenue trajectory. The at-scale scenario implies Imricor operates independently through most of the five-year window and realizes a full strategic premium at exit, which is the highest IRR outcome but requires the most execution.
Key Acquisition Comparables
Affera → Medtronic (2022): ~US$925m pre-revenue, EP mapping/ablation IP buy; Medtronic paid for the pipeline and regulatory pathway, not current earnings
Farapulse → Boston Scientific (2021): ~US$300m + milestones at minimal revenue, PFA catheter IP acquisition ahead of commercial scale; BSc then built Farapulse to >US$1bn in Year 1
Shockwave Medical → J&J (2024): US$13.1bn at ~18x trailing revenue, market leadership premium on 49% growth, defensible IP, large underpenetrated cardiovascular TAM
The common thread: Strategic acquirers in cardiac devices consistently pay for IP moats, regulatory approvals, and forward revenue trajectories, not current earnings. Imricor's combination of a 15-year IP portfolio, a complete validated ecosystem, and no credible competitor is precisely the profile that commands strategic premiums.
IX. Key Risks
The Imricor thesis carries genuine risks that warrant explicit consideration, ordered by their potential impact on the return outcome.
8.1 Regulatory Risk
The largest near-term binary is the FDA PMA decision on the ablation catheter. NorthStar's 510(k) clearance demonstrates FDA receptivity, but the PMA bar is substantially higher, prospective clinical evidence, manufacturing quality review, and FDA discretion over additional information requests. A 12-24 month delay beyond H2 2026 pushes the commercial inflection point by the same margin, extends the pre-revenue burn period, increases the capital required in FY27, and compresses the window for US traction within five years. This is the primary bear case mechanism.
8.2 Hospital Adoption Pace
Converting a pipeline hospital to a signed contract and installed lab requires navigating EP champion, administration, finance committee, facilities management, and radiology, across institutions with long budget cycles and competing capital priorities. The EU pipeline conversion rate from 40 active prospects to signed contracts in H1 2026 will be the most instructive leading indicator of the US commercial cadence. The unit economics in Section V show that reaching the base case requires 75 mature US labs by FY31, a concentrated, winnable market, but one that requires consistent execution across a five-year commercial build.
8.3 Pulse Field Ablation Competition
PFA has been the most consequential technology introduction in EP in a decade, Boston Scientific's Farapulse exceeded US$1 billion in its first full year. PFA is a non-thermal ablation energy source, not a visualization platform. It remains constrained by X-ray guidance, cannot confirm lesion durability in real time, and has limited demonstrated applicability in VT. Imricor is developing an MRI-compatible PFA catheter, which, if successful, combines MRI's visualization advantages with PFA's speed and tissue selectivity. Success here extends the addressable market rather than defending it.
8.4 Dilution Risk
Imricor exited FY25 with US$40.8 million in cash against approximately US$19 million in annual operating outflow. A US$35 million equity raise in H1 2027 is assumed, producing approximately 340 million diluted shares. A regulatory delay that extends the pre-revenue period would increase the quantum of the raise and, if the share price is depressed, its dilutive impact, the key bear case risk for share count assumptions.
X. Conclusion
Imricor occupies a position that is rare in medical technology: it is not competing at the margin of an established workflow but replacing the foundational imaging modality of an entire procedure category. Fluoroscopy guided cardiac ablation because MRI-compatible tools did not exist. Now they do, protected by fifteen years of IP, a validated complete ecosystem, an advancing US PMA, and no credible near-term competitor.
The unit economics are grounded and tractable. Each US hospital installation of approximately 500 procedures per year generates US$3 million in annual recurring revenue at roughly 71% gross margin. The base case, 75 mature US labs plus 28 EU labs by FY31, produces US$272 million in revenue, with US$67 million of EBITDA at 25% margins generating a 25% IRR from today's entry.
The near-term catalysts, VISABL-AFL readout, PMA module 3 FDA feedback, EU pipeline conversion in H1 2026, and the first US commercial installation, are each observable and arriving within the next twelve months. They will do more to resolve the probability weights across these scenarios than any amount of additional analysis.
Investment Framework Summary
Entry: US$436m market cap · A$1.95/sh · March 2026 · 5-year horizon to FY2031
Unit economics anchor: US$3m recurring revenue per US lab · ~500 procedures/yr · ~71% gross margin on recurring
Exit multiples: EV/EBITDA 18/20/25x · EV/FCF 24/24/30x · blended exit; IRR driven by earnings
Bear — (10)% IRR / 0.60x MOIC: US$182m FY31 revenue · 50 US + 20 EU labs · thin EBITDA margins
Base — 25% IRR / 3.05x MOIC: US$272m FY31 revenue · 75 US + 28 EU labs · US$67m EBITDA at 25% margins
Bull — 58% IRR / 9.87x MOIC: US$453m FY31 revenue · 125 US + 46 EU labs · US$172m EBITDA at 38% margins
Primary risk: FDA PMA delay of 12-24 months — the single largest variable for bear case realization
This document is for informational purposes only and does not constitute investment advice or a solicitation to invest. The author may hold positions in securities discussed. All financial projections are the author's independent estimates derived from publicly available information and do not represent company guidance. Investors should conduct their own due diligence and consult qualified financial advisers before making investment decisions.
Imricor Medical Systems
ASX: IMR · Early Commercial Stage · Medical Devices
The MRI Cath Lab
Investment Framework
Entry: A$1.95/sh · A$623m market cap · ~US$436m · March 2026
Horizon: 5 years to FY2031 · Single US$35m raise H1 2027 · 340m diluted shares at exit
Unit economics anchor: US$3m recurring revenue per top-100 US hospital at ~500 procedures/yr
Bear: ~(10)% IRR · 0.60x MOIC · 50 US labs, 20 EU labs, thin margins
Base: ~25% IRR · 3.05x MOIC · 75 US labs, 28 EU labs, $272m revenue
Bull: ~58% IRR · 9.87x MOIC · 125 US labs, 46 EU labs, $453m revenue
March 2026
This document is for informational purposes only and does not constitute investment advice. All financial estimates are the author's independent analysis. Figures in US$ unless stated.
TLDR
Imricor is building the first commercially viable MRI-guided cardiac ablation platform, a structural upgrade to a $12–14bn market still performed under X-ray. With a 15-year IP moat, no credible competitor, and a recurring consumable model, the business has the potential to compound into a high-margin installed-base story as adoption scales. At today’s valuation, the base case supports ~25% IRR with meaningful upside from both execution and strategic acquisition.
I. Company Overview
Imricor Medical Systems is a US-based medical device company founded in 2006 and listed on the Australian Securities Exchange (ASX: IMR). It is the only company in the world to have developed and commercially approved a suite of real-time MRI-compatible products for use in interventional cardiac procedures. The company's initial focus is the US$12-14 billion cardiac ablation market — the field of electrophysiology (EP) that treats life-threatening heart arrhythmias, which is currently conducted entirely under X-ray fluoroscopy. Imricor manufactures, sells, and licenses everything required to convert a hospital's existing MRI scanner into an interventional cardiac MRI (iCMR) laboratory capable of performing real-time MRI-guided ablation procedures. It captures 100% of the consumable revenue for every procedure performed in every lab it installs.
1.1 The Company's Origin and Technology Foundation
Steve Wedan, an electrical engineer who spent his career at GE Healthcare designing MRI and ultrasound systems, founded Imricor in 2006 after identifying the fundamental mismatch between what cardiac ablation requires and what fluoroscopy can provide. The original proof-of-concept for MRI-compatible cardiac catheters was developed at Johns Hopkins University, with the first paper published in 2008. Imricor licensed that foundational research and has spent the intervening fifteen years translating it into a commercially viable, fully validated product system. The company is headquartered and manufactures primarily in Minnesota. It listed on the ASX in August 2019, raising A$13 million at A$0.83 per share, and has since completed a series of equity raises totaling over A$200 million, most recently a A$70 million institutional placement in March 2025. As of December 2025 the company held US$40.8 million in cash with approximately 320.9 million shares on issue.
1.2 The Product Suite
Imricor's commercial proposition is an iCMR lab, a complete, purpose-built environment for performing real-time MRI-guided cardiac ablation. The lab consists of Imricor's own capital equipment, consumables, and software, combined with third-party MRI-safe peripherals and the hospital's existing MRI scanner. Every item Imricor sells or licences fits into one of three revenue categories.
Capital Equipment (one-time, ~50% gross margin)
The two pieces of capital equipment Imricor sells per lab installation are the RF5000 Ablation Generator and the MR Advantage EP Recorder/Stimulator. Together these are priced at approximately US$500,000-700,000 and constitute the hardware backbone of the iCMR lab. The ablation generator supplies and controls the radiofrequency energy delivered to the heart tissue. The EP recorder/stimulator captures intracardiac electrograms in real time, the electrical signals that tell the physician where the abnormal circuitry is, and can deliver pacing stimuli to provoke or assess arrhythmias during the procedure. Both are fully MRI-compatible, operating safely within the scanner's magnetic and radiofrequency environment without producing heat, artifacts, or interference.
NorthStar 3D Mapping System (annual licence, ~85% gross margin)
NorthStar is Imricor's proprietary 3D cardiac mapping and guidance platform, and arguably the most strategically important product in the portfolio. It is the central hub of every iCMR lab, the software layer that connects the MRI scanner, the catheters, and the physician. NorthStar receives real-time MRI images from the scanner, tracks the position of Imricor's catheters within the heart at approximately 20 updates per second using active tracking coils embedded in the catheter tips, builds a three-dimensional shell of the cardiac chamber from actual MRI anatomy, and overlays ablation target points and delivered energy markers onto the live image. The physician sees the heart, the catheter, and the ablation map simultaneously, in real time, without radiation.
Critically, NorthStar is vendor-neutral. It integrates with MRI scanners manufactured by GE, Siemens, and Philips — the three companies that together control essentially 100% of the global MRI installed base. A hospital does not need to replace its existing MRI scanner to install an iCMR lab; it only needs NorthStar and Imricor's consumables and capital equipment. NorthStar received CE Mark in Europe and FDA 510(k) clearance in the United States in January 2026. The US clearance was a significant milestone — it means Imricor can now have formal commercial conversations with US hospitals about full iCMR lab installation while the ablation catheter PMA progresses.
NorthStar is licensed at approximately US$100,000 per lab per year, creating an annuity-like recurring revenue stream that scales directly with the global installed base. As the installed base grows, this layer of predictable, high-margin license revenue compounds regardless of procedure volumes in any given month.
Consumables (~70% gross margin)
Consumables are the primary revenue engine at scale. Every procedure performed in an iCMR lab requires a set of single-use Imricor-manufactured devices, which the company sells directly at the following approximate US price points:
Product
Function
US ASP
Indication
Vision-MR Ablation Catheter 2.0
Delivers radiofrequency energy to target cardiac tissue; contains MRI tracking coils and passive LC filter circuitry
~$4,000 (AFL) ~$6,500 (VT/AF)
AFL (CE Mark); VT/AF (in development)
Vision-MR Diagnostic Catheter
Records intracardiac electrograms to map arrhythmia; guides catheter placement pre-ablation
Included in procedure ASP
All indications
Transseptal Puncture Kit
Enables safe crossing from the right to the left atrium — required for AF and some VT procedures
Included in procedure ASP
AF / left-sided VT
Dispersive Electrode
Large body patch that completes the radiofrequency electrical circuit; MRI-compatible formulation
Included in procedure ASP
All indications
NavTrac-MR Sterile Cables
MRI-shielded cables connecting catheters to the generator and EP recorder
Included in procedure ASP
All indications
The ablation catheter is the primary consumable value driver. It is Imricor's most complex manufactured product. Each catheter contains the proprietary passive LC filter architecture that makes MRI compatibility possible, an irrigated radiofrequency tip, MRI receive coils for active catheter tracking, and a fiber-optic temperature sensor. CE Mark approval for the second-generation Vision-MR Ablation Catheter 2.0 was received in 2025. US FDA PMA approval, the pathway for the ablation catheter and generator, is the critical remaining regulatory event, with the VISABL-AFL pivotal trial nearing completion and full PMA submission targeted for mid-2026.
1.3 Third-Party Lab Components
Several components of the iCMR lab are supplied by third-party partners rather than Imricor directly. These include MRI-compatible wireless headsets for team communication within the scanner room (Optoacoustics), a 12-lead ECG monitor (MiRTLE Medical), an MRI-safe defibrillator (MIPM), and in-room displays (Nordic NeuroLab). The MRI scanner itself, the most capital-intensive element, is purchased directly from GE, Siemens, or Philips; Imricor does not participate in scanner revenue. This ecosystem of validated third-party relationships took years to assemble and is itself a component of the competitive moat: any new entrant would need to replicate not just Imricor's catheters but the entire validated lab environment.
1.4 Regulatory Status and Clinical Program
Imricor has achieved CE Mark under the EU Medical Device Regulation, the most rigorous European framework, for the full AFL ablation product suite: ablation catheter, diagnostic catheter, NorthStar, generator, cables, and electrodes. This permits commercial sales across Europe for atrial flutter ablation today. In the United States, NorthStar is FDA-cleared via 510(k). The ablation catheter and generator are in Pre-Market Approval (PMA), with the VISABL-AFL clinical trial, the pivotal US study enrolling at Johns Hopkins, University of Virginia Health, Virginia Commonwealth University Health, and Oklahoma Heart Institute, nearing completion.
Two further trials are active. The VISABL-VT trial, which enrolled its first patient in April 2025 at Amsterdam University Medical Centre, is the pivotal European study for VT CE Mark and is progressing at three EU sites. A separate program of first-in-human PFA (pulse field ablation) catheter development under real-time MRI guidance has also been initiated, following the world's first in-vivo MRI-guided ventricular PFA ablation completed in 2025.
Imricor at a Glance
Founded: 2006 · Listed ASX: August 2019 · HQ: Minnesota, USA
Shares on issue: 320.9 million · Cash (Dec 2025): US$40.8m
Key products: NorthStar 3D Mapping System · Vision-MR Ablation Catheter 2.0 · RF5000 Generator · MR Advantage EP Recorder/Stimulator · Full consumable suite
Regulatory: CE Mark (full AFL suite) · NorthStar FDA 510(k) cleared Jan 2026 · Ablation catheter PMA in progress (US)
Clinical: VISABL-AFL (US PMA trial, 4 US sites) · VISABL-VT (EU CE Mark trial, 3 EU sites) · PFA catheter development underway
Market: US$12-14bn cardiac ablation market growing at ~15% CAGR · Three arrhythmia indications: AFL, VT, AF · Currently conducted 100% under X-ray
Revenue model: Capital sale (~$500-700k/lab) · NorthStar licence (~$100k/lab/yr) · Consumables (~$4,000-6,500/procedure) · 100% of consumable revenue captured per lab
II. Why MRI Is the Superior Modality
Cardiac ablation has been performed under X-ray fluoroscopy for four decades. The procedure requires navigating a catheter through a beating heart, identifying the precise fragment of tissue responsible for an electrical abnormality, applying energy to destroy it permanently, and confirming the result before closing. Fluoroscopy is a structurally poor fit for this job. It was engineered to image bone and calcified structures, not soft cardiac tissue. Everything the operator cannot see must be inferred from indirect markers.
1.1 The Four Failures of X-Ray
The first failure is anatomical visualization. Under fluoroscopy, operators build a three-dimensional map of the cardiac chamber by touching the catheter tip to hundreds of points on the wall, assembling a surface approximation that represents the anatomy but cannot show the tissue beneath it. In ventricular tachycardia, where the target is a narrow channel of surviving myocardium embedded within scar, this is an acute limitation. The channel sustaining the arrhythmia may be millimeters wide and invisible without the soft-tissue contrast that only MRI provides.
The second failure is lesion verification. When radiofrequency energy is delivered under X-ray, there is no way to confirm in real time whether the lesion is transmural, whether cell death is complete, or whether an unintended gap has been left. Electrical silence at the catheter tip is used as a proxy, but gaps in pulmonary vein isolation and incomplete cavotricuspid isthmus block are principal causes of arrhythmia recurrence. Published series for atrial flutter report 10-20% long-term recurrence after a single ablation; for atrial fibrillation, five-year recurrence exceeds 30%.
The third failure is procedure time. A complex VT ablation under fluoroscopy takes five to nine hours on average, driven by the time required to build the electroanatomic map before a single ablation can be delivered. Each additional hour occupies expensive infrastructure and burdens a hemodynamically fragile patient.
The fourth failure is radiation: each ablation exposes the physician to ionizing radiation equivalent to a chest CT. Physicians performing 300-400 cases per year accumulate a substantial cumulative dose, with documented occupational consequences including musculoskeletal injury from lead aprons, cataracts, and elevated cancer risk.
1.2 What Real-Time MRI Delivers
Real-time MRI provides live, high-resolution, multiplanar soft-tissue contrast of a beating heart. The operator sees the myocardium directly, distinguishes viable tissue from scar, and tracks the catheter relative to the anatomy as it actually exists, not as a reconstructed approximation. In VT, the arrhythmogenic scar channel is visible before the first catheter contact. In AFL, the cavotricuspid isthmus is confirmed against the actual tissue rather than an inferred map.
Ablation lesion assessment in real time is MRI's most distinctive clinical capability. Gadolinium-enhanced imaging identifies edema and necrosis within minutes of energy delivery, giving the operator direct confirmation that the lesion is complete before moving to the next target. Imricor's CE mark enabling trial in AFL demonstrated 100% arrhythmia-free survival at two-year follow-up versus the 70-80% typically reported in fluoroscopy-guided published series.
Procedure time compression, consumable savings, and radiation elimination follow from the visualization advantage. Removing the intracardiac echocardiography catheter, eliminating point-by-point mapping in VT, and reducing repositioning uncertainty all shorten procedures. Imricor's first-in-human ischemic VT ablation was completed in a fraction of the time required under fluoroscopy. These advantages compound: shorter procedures mean higher throughput; better first-procedure success means fewer repeat ablations; lower consumable cost means higher per-case margin for the hospital.
The Clinical Case
Superior visualization + real-time lesion confirmation + shorter procedures + zero radiation compounds into one outcome: higher first-procedure durability and fewer repeat ablations. These are not marginal improvements. They represent a categorical change in what the procedure can achieve and why the adoption curve, once established, is likely to be self-reinforcing as outcome data accumulates at scale.
III. Why This Is Hard to Build — and Why the Moat Is Real
If the clinical advantages are self-evident, why did it take fifteen years and one company to commercialize the solution? The answer is an intersection of engineering, ecosystem, and regulatory challenges that are individually demanding and collectively near-prohibitive for any new entrant.
2.1 The Electromagnetic Incompatibility Problem
An MRI scanner generates a magnetic field of 1.5 to 3 Tesla and pulses radiofrequency energy at the resonant frequency of hydrogen protons: 64 MHz at 1.5T, 128 MHz at 3T. Any conductive material inside the bore acts as an antenna: it absorbs the RF energy, develops dangerous localized heating at the electrode tip, and produces imaging artifacts that obscure the anatomy. A conventional ablation catheter is not merely suboptimal inside an MRI; it is actively dangerous.
Imricor's foundational innovation is a passive dual-filter circuit architecture embedded in the catheter. Distributed non-resonant inductors along the electrode wires limit RF-induced current build-up at the scanner's operating frequency. Resonant LC filters provide high impedance that reflects MRI-induced energy before it reaches the electrode tip. Ablation current, which operates at much lower frequencies, passes through the same circuit with negligible attenuation. The result: a catheter that simultaneously delivers therapeutic energy, records intracardiac electrograms, and is tracked in real time under MRI without heating, without artifacts, without any active component.
The impedance is fixed at manufacture by the coil geometry. No calibration, no power source, no software. This makes the catheter both reliable and manufacturable at scale. It is protected by 19 issued US patents and 71 granted foreign patents, covering catheter circuit architectures, tracking coil designs, cable technologies, and deflection mechanisms, with filing dates from 2010 to 2042.
2.2 The Full Ecosystem Problem
A cardiac ablation procedure requires a complete working environment: 3D cardiac mapping, electrogram recording and pacing, energy delivery control, patient monitoring, hemodynamic support, and emergency defibrillation all within a room dominated by a 1.5 Tesla magnetic field. Every instrument that enters the MRI suite must be purpose-built for this environment. Off-the-shelf hospital equipment cannot be used.
Imricor has assembled this complete ecosystem over fifteen years: the Vision-MR Ablation and Diagnostic Catheters; the NorthStar 3D Mapping System (vendor-neutral, works with GE, Siemens, and Philips); the MR Advantage EP Recorder/Stimulator; the RF5000 Ablation Generator; sterile cables, transseptal puncture kits, and dispersive electrodes. Third-party partnerships with Optoacoustics, MiRTLE Medical, and MIPM complete the lab. The vendor-neutral NorthStar architecture means hospitals with any of the three major MRI platforms can deploy iCMR without replacing their existing scanner.
2.3 The Regulatory Moat
The regulatory pathway for an MRI-compatible cardiac ablation platform is the pathway for a complete system; each component requiring independent authorization across multiple jurisdictions. In Europe, CE Mark under the Medical Device Regulation has been granted for the full AFL ablation product suite. In the United States, NorthStar has been cleared via 510(k). The ablation catheter and generator are progressing through Pre-Market Approval, with modules 1 and 2 submitted and module 3 approaching completion.
Any new entrant must design a full catheter system, establish MRI electromagnetic compatibility at the circuit level, run multi-site prospective clinical trials, and navigate a PMA process, a five to seven year timeline requiring hundreds of millions of dollars. Biotronik ran one patient in Germany and stopped. Clearpoint Neuro never approached cardiac ablation. The regulatory moat is not a temporary first-mover advantage. It is a structural barrier that deepens as Imricor accumulates clinical and commercial data.
Five Layers of Competitive Protection
• Proprietary passive circuit IP covering the fundamental electromagnetic compatibility problem (19 US patents, 71 foreign, 2010–2042)
• Complete validated lab ecosystem assembled over 15 years - catheters, generator, mapping system, cables, third-party partnerships
• CE Mark granted; US PMA advancing - not replicable quickly by any new entrant
• Deep KOL relationships at leading EP centers - four active VISABL-AFL US trial sites including Johns Hopkins and Oklahoma Heart Institute
• Vendor-neutral NorthStar compatible with GE, Siemens, and Philips - converts existing hospital MRI into an iCMR lab without scanner replacement
IV. Value Creation Across All Stakeholders
A technology platform achieves durable commercial success when adoption is independently rational for every party in the ecosystem. The iCMR platform is notable in that this alignment is near-complete. Patients, physicians, hospitals, and payers each have separate and mutually reinforcing incentives to adopt. The commercial question is not whether iCMR becomes standard of care. It is how fast the ecosystem converts.
3.1 Patients
The core promise for the patient is durability, a single curative procedure rather than a sequence of ablations separated by months of symptomatic recurrence. The AFL trial two-year follow-up data, 100% freedom from arrhythmia versus 70-80% under fluoroscopy, is directionally compelling: when the operator can see the target tissue and confirm the lesion is complete, the procedure works better. VT patients represent the most acute clinical case, typically post-infarction, often hemodynamically fragile, and historically underserved because the procedure is too arduous to offer routinely. Real-time MRI visualization of scar architecture could change the risk-benefit calculation for VT ablation across a much broader population.
3.2 Physicians
More precise visualization means more confident lesion delivery and fewer cases in which the operator ends the session uncertain whether the ablation is complete. For VT, where the substrate is invisible under fluoroscopy, the advantage is categorical. The radiation argument compounds this: physicians performing 300-400 ablations per year accumulate documented occupational exposure. Several KOLs enrolled in Imricor's trial program have explicitly cited radiation elimination as a meaningful benefit independent of the clinical outcomes data. The generation of electrophysiologists entering practice today has markedly higher awareness of this risk than their predecessors.
3.3 Hospitals
The unit economics argument is direct and grounded. Imricor's system eliminates the intracardiac echocardiography catheter (approximately US$2,000 per case) used in left-sided procedures, and removes the dedicated electroanatomic mapping catheter in VT and AF (approximately US$2,000 per case). Against Medicare reimbursement of approximately US$24,500 per ablation, and commercially insured cases at US$51,000-56,000, a US$4,000 per-case reduction in consumable cost flows directly to hospital margin. The iCMR lab is less expensive to run per procedure than the conventional fluoroscopy workflow.
Throughput is the amplifier. A VT ablation reducible from seven hours to three to four hours under MRI guidance allows a high-volume center to run two cases in the time that previously accommodated one. An MRI scanner's dual-use capability, diagnostic cardiac imaging between ablation sessions, extends the utilization argument beyond the EP lab. And for the 15-20 major US academic centers already with MRI infrastructure in cardiology, adding Imricor's system costs US$500,000-700,000, a fraction of the US$3-4 million required to replace a fluoroscopy system at end-of-service-cycle.
3.4 Payers
Existing reimbursement codes cover iCMR ablation without modification. AFL, AF, and VT ablation are reimbursed under APC 5213 at approximately US$24,500 per Medicare case; commercial rates run US$51,000-56,000. Reimbursement increased 8% between FY24 and FY25. The payer's long-term interest, lower total pathway cost through fewer repeat procedures, is aligned with the technology's clinical promise. No new payer negotiation is required for Imricor to generate revenue.
Stakeholder
Primary Value Driver
Mechanism
Patient
Higher single-procedure durability; zero radiation
AFL: 100% 2yr recurrence-free vs ~75% fluoroscopy; VT: direct scar visualization
Physician
Better visualization; radiation eliminated; faster complex cases
Zero occupational exposure; direct substrate imaging in VT; procedure time compression
Hospital
Lower per-case cost; higher throughput; dual-use MRI
~US$4k/case consumable savings; 2x throughput potential for long VT; $500k vs $4m capex
Payer
Lower lifetime pathway cost per patient
Fewer repeat ablations; existing APC 5213 codes apply; Medicare rate +8% FY24-25
V. Approval Timeline and Revenue Architecture
The Imricor investment reduces to three sequential variables: when does US FDA approval arrive, how quickly do hospitals install iCMR labs, and how fast do procedure volumes ramp within those labs. The clinical and moat arguments are established. The investment uncertainty is concentrated in the timing and cadence of execution across these three variables.
4.1 Regulatory Status
In Europe, CE Mark under the full Medical Device Regulation has been granted for the complete AFL ablation product suite allowing commercial sales across the EU now. The 40-hospital European pipeline represents active near-term revenue. In the United States, NorthStar has been FDA-cleared via 510(k), allowing Imricor to begin formal commercial discussions with US hospitals ahead of catheter approval. The ablation catheter and RF5000 Generator are in the PMA process: modules 1 and 2 submitted, module 3 approaching submission, with VISABL-AFL trial completion expected 1H 2026 and full PMA submission thereafter. Standard FDA PMA review runs 10-12 months, implying approval in H2 2026 in the base case.
The four active US VISABL-AFL trial sites, Johns Hopkins, University of Virginia Health, Virginia Commonwealth University Health, and Oklahoma Heart Institute, are among the most prestigious EP programs in the country. These are pre-seeded commercial accounts: staff are trained, labs are configured, and physicians are publicly committed to the technology. Post-approval, converting a trial site to a commercial account is a contract negotiation, not a new sales process.
The VISABL-VT trial enrolled its first patient in April 2025 and is advancing at three European sites. Trial completion and VT CE Mark are targeted for 2027, opening Europe's highest-value consumable category at US$6,500 per procedure and providing the clinical package for a US VT program.
4.2 Revenue Model
Imricor's revenue has three components with distinct margin profiles. Capital sales, the ablation generator, EP recorder/stimulator, and NorthStar system, generate US$500,000-700,000 per lab installed at approximately 50% gross margin. Annual NorthStar license fees of approximately US$100,000 per lab carry approximately 85% gross margin and build a recurring, predictable revenue base that scales with the installed count. Consumable sales, catheters, kits, cables, and electrodes priced at US$4,000-6,500 per procedure, carry approximately 70% gross margin and are the primary revenue and cash flow engine at scale.
As the revenue mix shifts from capital-heavy early installs toward consumable and licence-dominated recurring revenue, blended gross margin converges toward 65-70%. Fixed cost leverage, R&D plateauing at approximately US$11-13 million annually, G&A growing modestly, drives EBITDA margin expansion from gross margin gains. EBITDA profitability is expected from FY29 onward in the base case. Free cash flow conversion from EBITDA at scale is estimated at approximately 80%, reflecting light capital expenditure requirements and modest working capital growth as procedures ramp.
VI. Unit Economics: Building Revenue from the Lab Up
The revenue scenarios in Section VI are not derived from top-down market penetration assumptions. They are built from the bottom up, starting with a single installed iCMR lab and scaling the number of labs installed across geographies and years. This section lays out the unit economics behind each lab, so the revenue assumptions can be stress-tested against what individual hospitals are expected to contribute.
5.1 The Economics of a Single US iCMR Lab
The anchor assumption, informed by Imricor's own investor materials and cross-checked against EP procedure volume data at large US academic centers, is approximately US$3 million in annual recurring revenue per top-100 US hospital, based on approximately 500 ablation procedures per year per iCMR lab. This figure combines consumable revenue and annual license fees.
Per-Lab Unit Economics: Top-100 US Hospital
Procedure volume: ~500 procedures per year per iCMR lab
Procedure mix: AFL (~30% of eligible cases), VT (~100% of referred cases), AF (~20% of recurrent cases)
Blended consumable ASP: ~US$5,500 (AFL at $4,000; VT and AF at $6,500)
Consumable revenue: 500 procedures × US$5,500 = US$2,750,000 per year
NorthStar license: US$100,000 per year
Service fees: US$150,000 per year
Total recurring revenue: US$3,000,000 per year per lab
One-time capital revenue: US$600,000 (generator + EP recorder/stimulator) — recognized at installation
Gross profit on recurring: Consumables at 70% = $1,925k · License at 85% = $85k · Service at 85% = $128k
Recurring gross margin: ~$2,138k / $3,000k = ~71% blended gross margin on recurring revenue
The 500-procedure-per-year assumption is conservative relative to the volumes at the largest US academic EP centers. Imricor's own data shows that the top 50 US hospitals by volume perform on average 434 AFL, 173 VT, and 1,010 AF procedures annually, a total addressable pool of approximately 1,617 ablation procedures per hospital, of which 500 represents a 30-35% penetration rate. As physician familiarity grows, lab utilization increases, and the VT and eventually AF indications open, the per-lab revenue figure has meaningful upside from this base.
5.2 EU and ROW Lab Economics
European and ROW hospitals generate lower per-procedure revenue for Imricor due to lower consumable ASPs, reflecting different reimbursement structures and purchasing dynamics. We model EU consumable revenue at approximately US$1,500-2,500 per procedure for AFL (versus US$4,000 in the US) and approximately US$3,500-4,000 for VT and AF (versus US$6,500 in the US). At ~300 procedures per EU lab per year, this produces approximately US$0.9-1.2 million in annual recurring revenue per EU iCMR lab, roughly half the US figure. Capital revenue per EU lab is approximately US$300,000.
5.3 Revenue Build by Installed Base
The table below shows the direct relationship between the number of installed labs and annual recurring revenue, providing a simple bridge between the lab count in each scenario and the revenue targets. Capital revenue, which is lumpy and depends on the pace of new installations in any given year, is shown separately, using a conservative assumption that 25% of the installed base represents new installs in each year (reflecting an accelerating install curve).
US Labs (Mature)
EU Labs (Mature)
US Recurring
EU Recurring
Total Recurring
Est. Capital p.a.
25
9
$75m
$10m
$85m
+$5m
50
19
$150m
$21m
$171m
+$11m
75
28
$225m
$31m
$256m
+$16m
100
37
$300m
$41m
$341m
+$21m
125
46
$375m
$51m
$426m
+$27m
150
56
$450m
$62m
$512m
+$32m
The US TAM extends well beyond 150 hospitals. Any hospital with an MRI scanner and an active EP program is a potential iCMR site, a population of over 1,200 institutions in the US alone.
5.4 Procedure Ramp Within Installed Labs
Labs do not operate at full utilization immediately upon installation. Staff training, physician scheduling, and patient referral network development mean that a newly installed iCMR lab typically reaches 60% of its steady-state procedure volume in the first year and full utilization by year two. This ramp effect means that the installed base at any point in time generates less revenue than a fully mature installed base of the same size, and it is one of the reasons the revenue trajectory in the early years of a scenario can appear slow relative to the eventual run-rate contribution of each lab installed.
The year-by-year revenue trajectory in each scenario in Section VI accounts for this ramp, applying a 50-60% utilization assumption in the year of installation and full utilization from the following year. New capital installations in each year generate proportionally lower consumable revenue than the existing base — which is why revenue growth accelerates as the installed base matures and procedures deepen within each lab.
VII. Return Analysis: A 5-Year IRR Framework
We frame the investment as a return question: given the current entry market capitalization, what does the company need to become by FY2031 to generate a target return? We present a range of valuation methodologies benchmarked against comparable MedTech M&A transactions and public comps.
6.1 Framework and Assumptions
Entry market capitalization: approximately A$622 million (US$436 million at A$/USD 0.70). Holding period: five years to FY2031. A single equity raise of approximately US$35 million in H1 2027 results in approximately 340 million diluted shares at the exit date, the only dilution modeled. EBITDA and FCF multiples of 16-25x and 20-30x respectively are consistent with comparable medical device companies at similar stages of recurring revenue scale.
6.2 Margin Assumptions
The margin build from near-zero gross profit today to the FY31 profiles below is driven by the mix shift from capital sales (50% gross margin) to consumables and licenses (70-85% gross margin) as the installed base grows, and by fixed cost leverage as R&D and G&A grow more slowly than revenue. FCF conversion from EBITDA is estimated at approximately 78-84% at scale, reflecting light capital expenditure and manageable working capital growth.
Margin Metric
FY26E (Base)
FY28E (Base)
FY31E Bear
FY31E Base
FY31E Bull
Blended Gross Margin
~22%
~58%
~55%
~66%
~70%
EBITDA Margin
Neg
~5%
~8%
~25%
~38%
FCF Margin
Neg
Neg
~6%
~20%
~32%
FCF / EBITDA Conversion
n/m
n/m
~75%
~80%
~84%
R&D (US$m)
~$10
~$11
~$12
~$13
~$16
G&A (US$m)
~$6
~$7
~$8
~$10
~$13
6.3 Revenue Trajectory
Revenue in each scenario is anchored to the lab counts at FY31: 50 US + 20 EU labs in the bear, 75 US + 28 EU in the base, and 125 US + 46 EU in the bull. The year-by-year build reflects EU commercial momentum in FY26-27, US commercial launch following FDA approval in FY27-28, and procedure ramp deepening within the global installed base through FY29-31. The VT CE Mark in 2027 is the most significant single revenue catalyst within the forecast period. It opens the US$6,500 per procedure consumable category across the growing installed base.
FY26E
FY27E
FY28E
FY29E
FY30E
FY31E
Bear Revenue (US$m)
$4
$8
$20
$60
$115
$182
Base Revenue (US$m)
$4
$12
$55
$120
$195
$272
Bull Revenue (US$m)
$6
$20
$90
$200
$330
$453
Bear Global Lab Count
4
6
15
35
55
70
Base Global Lab Count
6
12
30
60
88
103
Bull Global Lab Count
8
20
55
105
145
171
6.4 Scenario Outcomes and IRR
The IRR in each scenario is driven by the EV/EBITDA exit multiple applied to the EBITDA the company generates at its FY31 revenue level. FCF is shown for reference, and the implied EV/FCF multiple — derived from the same exit EV — serves as a reasonableness check. EV/Revenue is shown as a comp check as well.
Metric
Bear Case
Base Case
Bull Case
FY31E Revenue (US$m)
$182m
$272m
$453m
── Recurring (consumables + lic)
$171m
$250m
$426m
── Capital (installations)
$11m
$16m
$27m
FY31E US / EU Labs
50 / 20
75 / 28
125 / 46
FY31E Gross Margin
~55%
~66%
~70%
FY31E EBITDA (US$m)
$15m
$68m
$172m
FY31E EBITDA Margin
~8%
~25%
~38%
FY31E Free Cash Flow (US$m)
$11m
$53m
$145m
FY31E FCF Margin
~6%
~20%
~32%
── EV/EBITDA exit multiple
18x
20x
25x
Exit EV (US$m)
$270m
$1,330m
$4,304m
─── 5-Year IRR
(10)%
25%
58%
─── 5-Year MOIC
0.60x
3.05x
9.87x
Implied A$/share
A$1.10
A$5.59
A$18.08
Implied EV/FCF (cross-check)
24.0x
25.0x
29.7x
Implied EV/Revenue (cross-check)
1.4x
5.0x
9.5x
6.5 Gross Profit Sensitivity
A strategic acquirer would likely evaluate Imricor within the context of its own cost structure, where existing sales, R&D, and G&A capabilities may reduce the relevance of standalone EBITDA. In that setting, EV relative to gross profit can be a useful framing.
The grid below fixes the gross margin at 66%, the base case assumption, and shows the 5-year IRR at each lab count and EV/GP multiple. Each row represents a different installed base at maturity; the gross profit at each row is purely a function of the recurring revenue those labs generate. The base case row, 75 US labs plus 28 EU labs producing US$179 million of gross profit, requires approximately 8x EV/GP to generate a ~25% IRR from today's entry. Rows above it represent faster adoption curves; the multiple required to hit 25% IRR falls as the installed base grows.
Lab Count (GP at 66% GM) \ EV/GP
4x
5x
6x
7x
8x
9x
10x
25 US + 9 EU ($60m GP)
-11%
-7%
-4%
-1%
2%
4%
6%
50 US + 19 EU ($120m GP)
2%
7%
11%
14%
17%
20%
22%
75 US + 28 EU ($179m GP) ← base
10%
16%
20%
24%
27%
30%
33%
100 US + 37 EU ($239m GP)
17%
22%
27%
31%
34%
38%
41%
125 US + 46 EU ($298m GP)
22%
28%
33%
37%
41%
44%
47%
150 US + 56 EU ($359m GP)
27%
33%
38%
42%
46%
49%
52%
Gross margin fixed at 66%. GP = (US labs × $3.0m + EU labs × $1.1m + capital) × 66%. Green ≥25% Teal 15–24% Amber 0–14% Red Negative · Entry = US$436m · 5-year horizon
VIII. Acquisition Analysis
In our view, the most likely outcome for Imricor is an acquisition by one of the large MedTech or imaging companies for whom owning this platform is strategically compulsory. Every major player in cardiac electrophysiology or MRI has either tried and failed to build what Imricor has built, or operates a franchise that Imricor's technology directly threatens or enhances. The IP, the regulatory approvals, and the installed base are not replicable on any reasonable timeline, which is precisely the condition under which strategic acquirers pay the largest premiums.
This section is intentionally separate from the earnings-driven return analysis in Section VII. The acquisition scenario does not depend on Imricor reaching a specific EBITDA margin or FCF conversion rate. It depends on a strategic buyer deciding that the cost of acquiring the platform is lower than the cost of competing against it or rebuilding it internally, a calculation that favors acquisition across a wide range of revenue and margin outcomes.
7.1 Who Buys This and Why
There are six credible acquirers, each with a distinct and specific rationale.
Acquirer
Strategic Rationale
What They Get
GE HealthCare
NorthStar runs natively on GE MRI scanners. Acquiring Imricor converts GE's existing cardiology MRI installed base, thousands of scanners already in EP-capable hospitals, into a recurring procedural revenue stream. Every GE scanner becomes a potential iCMR lab without a scanner replacement cycle.
Installed base monetization; procedure revenue on existing hardware; lock-in for next MRI refresh cycle
Siemens Healthineers
Siemens has been the most aggressive of the three MRI majors in pursuing imaging-therapy convergence. Their ARTIS icono hybrid OR platform reflects exactly this strategic intent. iCMR is the cardiac ablation expression of that strategy, and Siemens has no internal program in this space.
Cardiac therapy convergence; completes EP strategy without years of development; vendor-neutral NorthStar flips to Siemens-preferred
Philips
Philips attempted MRI-guided cardiac therapy internally and discontinued the program. They carry the institutional knowledge of how hard this problem is and the cost of having failed. Acquiring Imricor eliminates the competitor they failed to build and re-enters the market with a proven system.
Eliminates existential competitive gap; re-entry into MRI-guided therapy; IP acquisition removes rebuild risk entirely
Medtronic
Medtronic acquired Affera in 2022 for ~US$925 million pre-revenue, specifically to enter the EP mapping and navigation market. Affera operates under fluoroscopy. Imricor adds the MRI imaging layer that Affera lacks, combining with Medtronic's existing ablation catheter portfolio to create the only fully integrated conventional + MRI EP platform.
MRI layer for Affera; complete multi-modality EP franchise; VT substrate mapping advantage across both fluoroscopy and MRI labs
Boston Scientific
BSc's Farapulse PFA platform exceeded US$1 billion in its first full year. Farapulse operates under X-ray. Imricor is developing an MRI-compatible PFA catheter — a product that, if it reaches market independently, becomes the direct competitive threat to Farapulse in high-complexity AF and VT. Acquiring Imricor before that product matures removes the threat and adds MRI capability to the BSc EP franchise.
Pre-empts MRI-PFA competitive threat; adds MRI guidance to Farapulse ecosystem; VT market entry via iCMR
J&J / Biosense Webster
Biosense Webster's CARTO system is the global standard for EP mapping under fluoroscopy. Imricor's NorthStar is, structurally, CARTO for the MRI era, the same mapping and guidance role, executed under a superior imaging modality. J&J has spent over US$30 billion on cardiac MedTech since 2022. Adding iCMR capability extends the Biosense Webster franchise into the next imaging generation.
NorthStar as CARTO successor platform; dominant mapping franchise extended to MRI; natural evolution of $30bn+ cardio build-out
7.2 Acquisition Timing and Valuation
The relevant precedent transactions establish the valuation framework. Medtronic paid approximately US$925 million for Affera in 2022, a pre-revenue EP mapping and ablation company with investigational technology, no commercial sales, and a single pivotal trial in progress. The strategic rationale was identical to the case for acquiring Imricor: filling a gap in the EP portfolio that could not be bridged through internal R&D on a competitive timeline. J&J paid approximately US$13.1 billion for Shockwave Medical in 2024 at roughly 18x trailing revenue, on 49% annual revenue growth, for a platform with genuine market leadership and defensible IP in a large underpenetrated cardiovascular market. These two transactions bracket the Imricor acquisition spectrum, from IP buy at minimal revenue to scale premium at established growth.
Imricor's most relevant comp at any acquisition point is not a company at steady-state earnings. It is a platform with a patented technology moat, a complete validated ecosystem that took 15 years to assemble, regulatory approvals that no competitor has replicated, and a recurring consumable model that accelerates as labs mature. Acquirers in this category routinely pay on forward revenue trajectory rather than current earnings, and the strategic premium reflects the cost of the alternative: attempting to rebuild the platform internally, which the three MRI OEMs, Medtronic, BSc, and J&J have all either tried and failed or explicitly chosen not to attempt.
7.3 Acquisition Scenario Outcomes
The table below shows indicative acquisition outcomes across three timing scenarios. Revenue multiples are applied to estimated revenue at each acquisition date, using a range of multiples anchored to comparable cardiac MedTech transactions. IRRs are computed from the current entry market cap of US$436 million. A pre-revenue or near-revenue acquisition (FY26-27) is treated as an IP and pipeline acquisition analogous to Affera, with an absolute EV range rather than a revenue multiple.
Scenario
Timing
Est. Revenue
EV Range (US$m)
Multiple Basis
IRR Range
A$/Share
Pre-approval / IP buy
FY26-27 (1-2 yrs)
US$10-30m
$800m – $1,500m
IP + regulatory pathway; Affera comp ($925m pre-rev)
50–100%+
A$3.36 – A$6.30
Early commercial
FY28 (~3 yrs)
US$50-80m
$780m – $1,200m
12–18x EV/Rev; 50-80 labs installed
21–40%
A$3.28 – A$5.04
At scale
FY30-31 (~5 yrs)
US$220-330m
$2,200m – $5,000m
10–15x EV/Rev; 100+ US labs, VT + AF
38–62%
A$9.24 – A$21.01
A few observations on this table. The pre-approval scenario IRR is very high but also the least probable: large MedTech acquirers move slowly, and a transaction before FDA PMA approval carries regulatory risk that most buyers price conservatively. The most likely acquisition window is the early commercial phase, FY28, after the US commercial model has been validated by 30-50 lab installations but before the revenue trajectory is fully visible. This is when acquirers have sufficient data to underwrite the platform while the target's negotiating position has not yet fully reflected the bull case revenue trajectory. The at-scale scenario implies Imricor operates independently through most of the five-year window and realizes a full strategic premium at exit, which is the highest IRR outcome but requires the most execution.
Key Acquisition Comparables
Affera → Medtronic (2022): ~US$925m pre-revenue, EP mapping/ablation IP buy; Medtronic paid for the pipeline and regulatory pathway, not current earnings
Farapulse → Boston Scientific (2021): ~US$300m + milestones at minimal revenue, PFA catheter IP acquisition ahead of commercial scale; BSc then built Farapulse to >US$1bn in Year 1
Shockwave Medical → J&J (2024): US$13.1bn at ~18x trailing revenue, market leadership premium on 49% growth, defensible IP, large underpenetrated cardiovascular TAM
The common thread: Strategic acquirers in cardiac devices consistently pay for IP moats, regulatory approvals, and forward revenue trajectories, not current earnings. Imricor's combination of a 15-year IP portfolio, a complete validated ecosystem, and no credible competitor is precisely the profile that commands strategic premiums.
IX. Key Risks
The Imricor thesis carries genuine risks that warrant explicit consideration, ordered by their potential impact on the return outcome.
8.1 Regulatory Risk
The largest near-term binary is the FDA PMA decision on the ablation catheter. NorthStar's 510(k) clearance demonstrates FDA receptivity, but the PMA bar is substantially higher, prospective clinical evidence, manufacturing quality review, and FDA discretion over additional information requests. A 12-24 month delay beyond H2 2026 pushes the commercial inflection point by the same margin, extends the pre-revenue burn period, increases the capital required in FY27, and compresses the window for US traction within five years. This is the primary bear case mechanism.
8.2 Hospital Adoption Pace
Converting a pipeline hospital to a signed contract and installed lab requires navigating EP champion, administration, finance committee, facilities management, and radiology, across institutions with long budget cycles and competing capital priorities. The EU pipeline conversion rate from 40 active prospects to signed contracts in H1 2026 will be the most instructive leading indicator of the US commercial cadence. The unit economics in Section V show that reaching the base case requires 75 mature US labs by FY31, a concentrated, winnable market, but one that requires consistent execution across a five-year commercial build.
8.3 Pulse Field Ablation Competition
PFA has been the most consequential technology introduction in EP in a decade, Boston Scientific's Farapulse exceeded US$1 billion in its first full year. PFA is a non-thermal ablation energy source, not a visualization platform. It remains constrained by X-ray guidance, cannot confirm lesion durability in real time, and has limited demonstrated applicability in VT. Imricor is developing an MRI-compatible PFA catheter, which, if successful, combines MRI's visualization advantages with PFA's speed and tissue selectivity. Success here extends the addressable market rather than defending it.
8.4 Dilution Risk
Imricor exited FY25 with US$40.8 million in cash against approximately US$19 million in annual operating outflow. A US$35 million equity raise in H1 2027 is assumed, producing approximately 340 million diluted shares. A regulatory delay that extends the pre-revenue period would increase the quantum of the raise and, if the share price is depressed, its dilutive impact, the key bear case risk for share count assumptions.
X. Conclusion
Imricor occupies a position that is rare in medical technology: it is not competing at the margin of an established workflow but replacing the foundational imaging modality of an entire procedure category. Fluoroscopy guided cardiac ablation because MRI-compatible tools did not exist. Now they do, protected by fifteen years of IP, a validated complete ecosystem, an advancing US PMA, and no credible near-term competitor.
The unit economics are grounded and tractable. Each US hospital installation of approximately 500 procedures per year generates US$3 million in annual recurring revenue at roughly 71% gross margin. The base case, 75 mature US labs plus 28 EU labs by FY31, produces US$272 million in revenue, with US$67 million of EBITDA at 25% margins generating a 25% IRR from today's entry.
The near-term catalysts, VISABL-AFL readout, PMA module 3 FDA feedback, EU pipeline conversion in H1 2026, and the first US commercial installation, are each observable and arriving within the next twelve months. They will do more to resolve the probability weights across these scenarios than any amount of additional analysis.
Investment Framework Summary
Entry: US$436m market cap · A$1.95/sh · March 2026 · 5-year horizon to FY2031
Unit economics anchor: US$3m recurring revenue per US lab · ~500 procedures/yr · ~71% gross margin on recurring
Exit multiples: EV/EBITDA 18/20/25x · EV/FCF 24/24/30x · blended exit; IRR driven by earnings
Bear — (10)% IRR / 0.60x MOIC: US$182m FY31 revenue · 50 US + 20 EU labs · thin EBITDA margins
Base — 25% IRR / 3.05x MOIC: US$272m FY31 revenue · 75 US + 28 EU labs · US$67m EBITDA at 25% margins
Bull — 58% IRR / 9.87x MOIC: US$453m FY31 revenue · 125 US + 46 EU labs · US$172m EBITDA at 38% margins
Primary risk: FDA PMA delay of 12-24 months — the single largest variable for bear case realization
Catalyst
VISABL-AFL readout, PMA module 3 FDA feedback, EU pipeline conversion in H1 2026, and the first US commercial installation
v. 4.20
